Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell ...

BOSTON, March 4, 2025 /PRNewswire/ -- Bluebird Kids Health, a new healthcare services company designed to deliver value-based pediatric primary care, today announced the closing of a $31.5 million ...